{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:34:06Z","timestamp":1791866046209,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01244-x","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:20:32Z","timestamp":1789143632000},"page":"799-806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Osimertinib Plus Platinum\u2013Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC"],"prefix":"10.1007","volume":"21","author":[{"given":"Amy","family":"Zhuang-Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"3","key":"1244_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1244_CR2","unstructured":"World Health Organization. Lung cancer. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer. Accessed 10 June 2026."},{"key":"1244_CR3","unstructured":"National Comprehensive Cancer Network\u00ae. Clinical practice guidelines in oncology (NCCN Guidelines\u00ae): non-small cell lung cancer (version 3.2026). 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 10 June 2026."},{"key":"1244_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472784","author":"G La Cava","year":"2025","unstructured":"La Cava G, Cortellini A, Rotow JK, et al. Navigating first-line treatment options for patients with epidermal growth factor receptor-positive non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2025. https:\/\/doi.org\/10.1200\/EDBK-25-472784.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1244_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","volume":"18","author":"PL Su","year":"2025","unstructured":"Su PL, Furuya N, Asrar A, et al. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematol Oncol. 2025;18(1):35.","journal-title":"J Hematol Oncol"},{"key":"1244_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1241402","author":"M Yang","year":"2024","unstructured":"Yang M, Mandal E, Liu FX, et al. Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2023.1241402.","journal-title":"Front Oncol"},{"issue":"1","key":"1244_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","volume":"18","author":"S Popat","year":"2023","unstructured":"Popat S, Ahn MJ, Ekman S, et al. Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies. Target Oncol. 2023;18(1):9\u201324.","journal-title":"Target Oncol"},{"issue":"9","key":"1244_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361.","journal-title":"Cancer Discov"},{"issue":"4","key":"1244_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357.","journal-title":"Ann Oncol"},{"key":"1244_CR10","unstructured":"Hendriks LE, Cortiula F, Mariamidze E, et al. ESMO oncogene-addicted non-small cell lung cancer living guideline v1.2. 2025. https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-oncogene-addicted-metastatic-non-small-cell-lung-cancer. Accessed 10 June 2026."},{"issue":"1","key":"1244_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-019-1240-x","volume":"38","author":"S La Monica","year":"2019","unstructured":"La Monica S, Minari R, Cretella D, et al. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res. 2019;38(1):222.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"1244_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115\u201323.","journal-title":"J Clin Oncol"},{"key":"1244_CR13","unstructured":"AstraZeneca. Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer [media release]. 2024. https:\/\/www.astrazeneca.com."},{"key":"1244_CR14","unstructured":"European Medicines Agency. Tagrisso film-coated tablets: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tagrisso-epar-product-information_en.pdf. Accessed 10 June 2026."},{"key":"1244_CR15","unstructured":"AstraZeneca. Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer [media release]. 2024. https:\/\/www.astrazeneca.com."},{"key":"1244_CR16","unstructured":"AstraZeneca Pharmaceuticals LP. TAGRISSO\u00ae (osimertinib) tablets, for oral use 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208065s033lbl.pdf. Accessed 10 June 2026."},{"issue":"5","key":"1244_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11523-021-00839-w","volume":"16","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC. Target Oncol. 2021;16(5):687\u201395.","journal-title":"Target Oncol"},{"issue":"3","key":"1244_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-022-00883-0","volume":"17","author":"JE Frampton","year":"2022","unstructured":"Frampton JE. Osimertinib: a review in completely resected, early-stage, EGFR mutation-positive NSCLC. Target Oncol. 2022;17(3):369\u201376.","journal-title":"Target Oncol"},{"issue":"4","key":"1244_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11523-017-0519-0","volume":"12","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Scott LJ. Osimertinib: a review in T790M-positive advanced non-small cell lung cancer. Target Oncol. 2017;12(4):555\u201362.","journal-title":"Target Oncol"},{"issue":"21","key":"1244_CR20","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"key":"1244_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.023","volume":"185","author":"R Saito","year":"2023","unstructured":"Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL study. Eur J Cancer. 2023;185:83\u201393.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1244_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100271","volume":"6","author":"D Planchard","year":"2021","unstructured":"Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021;6(5):100271.","journal-title":"ESMO Open"},{"issue":"11","key":"1244_CR23","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jtho.2023.09.009","volume":"18","author":"P J\u00e4nne","year":"2023","unstructured":"J\u00e4nne P, Planchard D, Cheng Y, et al. Osimertinib with\/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2) [abstract no. PL03.13]. J Thorac Oncol. 2023;18(11):S36\u20137.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1244_CR24","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jtho.2024.09.185","volume":"19","author":"N Valdiviezo","year":"2024","unstructured":"Valdiviezo N, Gray JE, J\u00e4nne PA, et al. FLAURA2: impact of tumor burden on outcomes of 1L osimertinib \u00b1 chemotherapy in patients with EGFR-mutated advanced NSCLC [abstract no. MA12.04]. J Thorac Oncol. 2024;19(10):S102.","journal-title":"J Thorac Oncol"},{"issue":"S4","key":"1244_CR25","doi-asserted-by":"publisher","first-page":"S1635","DOI":"10.1016\/j.annonc.2024.10.663","volume":"35","author":"JCH Yang","year":"2024","unstructured":"Yang JCH, Kobayashi K, Chewaskulyong B, et al. First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort [abstract no. 630MO]. Ann Oncol. 2024;35(S4):S1635\u20136.","journal-title":"Ann Oncol"},{"issue":"S3","key":"1244_CR26","first-page":"1","volume":"9","author":"N Valdiviezo","year":"2024","unstructured":"Valdiviezo N, Okamoto I, Hughes BGM, et al. First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes [abstract no. 4O]. ESMO Open. 2024;9(S3):1.","journal-title":"ESMO Open"},{"issue":"Suppl 7","key":"1244_CR27","first-page":"CT107","volume":"84","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne PA, Kobayashi K, Robichaux J, et al. FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed [abstract]. Cancer Res. 2024;84(Suppl 7):CT107.","journal-title":"Cancer Res"},{"issue":"1","key":"1244_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","volume":"394","author":"PA Janne","year":"2026","unstructured":"Janne PA, Planchard D, Kobayashi K, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394(1):27\u201338.","journal-title":"N Engl J Med"},{"issue":"7","key":"1244_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2024;42(7):808\u201320.","journal-title":"J Clin Oncol"},{"issue":"S3","key":"1244_CR30","first-page":"7","volume":"9","author":"CK Lee","year":"2024","unstructured":"Lee CK, Cheng Y, Laktionov K, et al. First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs) [abstract no. 9P]. ESMO Open. 2024;9(S3):7.","journal-title":"ESMO Open."},{"issue":"S3","key":"1244_CR31","first-page":"7","volume":"9","author":"CK Lee","year":"2024","unstructured":"Lee CK, Planchard D, Fan Y, et al. Safety and tolerability of first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFRm advanced NSCLC: data from FLAURA2 [abstract no. 10P]. ESMO Open. 2024;9(S3):7\u20138.","journal-title":"ESMO Open."},{"issue":"24","key":"1244_CR32","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1200\/JCO-25-01061","volume":"43","author":"JE Reuss","year":"2025","unstructured":"Reuss JE, Kuruvilla S, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025.1. J Clin Oncol. 2025;43(24):e31\u201344.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1244_CR33","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","volume":"21","author":"R Shah","year":"2020","unstructured":"Shah R, Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations. Clin Lung Cancer. 2020;21(3):e216\u201328.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1244_CR34","first-page":"373","volume":"75","author":"LJ Antrim","year":"2025","unstructured":"Antrim LJ, Malhotra J. Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach. CA Cancer J Clin. 2025;75(5):373\u20135.","journal-title":"CA Cancer J Clin"},{"key":"1244_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103776","author":"T Mei","year":"2025","unstructured":"Mei T, Wang T, Xu T, et al. Comparing the effectiveness and safety of first-line interventions in patients with advanced epidermal growth factor receptor-mutant non-small cell lung cancer, with particular focus on brain metastatic status: a systematic review and network meta-analysis. Clin Oncol. 2025. https:\/\/doi.org\/10.1016\/j.clon.2025.103776.","journal-title":"Clin Oncol"},{"key":"1244_CR36","unstructured":"National Institute for Health and Care Excellence. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR-mutation-positive advanced non-small cell lung cancer. 2025. https:\/\/www.nice.org.uk\/guidance\/ta1060\/chapter\/1-Recommendation. Accessed 10 June 2026."},{"key":"1244_CR37","unstructured":"Scottish Medicines Consortium. Osimertinib film-coated tablet (Tagrisso\u00ae). 2025. https:\/\/scottishmedicines.org.uk\/media\/9260\/osimertinib-tagrisso-final-june-2025-for-website.pdf. Accessed 10 June 2026."},{"key":"1244_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70083","author":"W Tian","year":"2024","unstructured":"Tian W, Niu L, Zhou R, et al. Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Med. 2024. https:\/\/doi.org\/10.1002\/cam4.70083.","journal-title":"Cancer Med"},{"issue":"6","key":"1244_CR39","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.jval.2025.04.1997","volume":"28","author":"H Freeman","year":"2025","unstructured":"Freeman H, Upton E, Karia PS, et al. Cost comparison of osimertinib plus chemotherapy versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic EGFR-mutated NSCLC [abstract no. EE398]. Value Health. 2025;28(6):S135\u20136.","journal-title":"Value Health."},{"issue":"5","key":"1244_CR40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/cpt.3759","volume":"118","author":"J Yang","year":"2025","unstructured":"Yang J, Olabode D, Sawant-Basak A, et al. Population pharmacokinetics and exposure-response analysis of first-line osimertinib plus chemotherapy in patients with EGFR-mutated advanced NSCLC. Clin Pharmacol Ther. 2025;118(5):1110\u201321.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01244-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01244-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01244-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:52:07Z","timestamp":1790916727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01244-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01244-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The preparation of this review was not supported by any external funding.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy Zhuang-Yan and Yahiya Y. Syed are salaried employees of Adis International Ltd\/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}